Accessibility Menu
Traws Pharma Stock Quote

Traws Pharma (NASDAQ: ONTX)

$2.67
(-10.4%)
-0.31
Price as of October 22, 2025, 3:33 p.m. ET

KEY DATA POINTS

Current Price
$2.68
Daily Change
(-10.4%) $0.31
Day's Range
$2.65 - $2.97
Previous Close
$2.68
Open
$2.9
Beta
0.98
Volume
118,868
Average Volume
160,943
Market Cap
21.2M
Market Cap / Employee
$2.98M
52wk Range
$0.97 - $19.44
Revenue
-
Gross Margin
1.00%
Dividend Yield
N/A
EPS
$15.61
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Traws Pharma Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ONTX-44.77%-97.46%-52.05%-100%
S&P+15.06%+95.03%+14.29%+298%

Traws Pharma Company Info

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$2.73M4694.7%
Gross Profit$2.73M5054.7%
Gross Margin99.96%7.0%
Market Cap$8.24M-12.6%
Market Cap / Employee$1.18M0.0%
Employees7-58.8%
Net Income-$0.63M99.5%
EBITDA-$1.25M78.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$13.08M-22.5%
Accounts Receivable$1.32M7250.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets512.48%1070.1%
Return On Invested Capital-102.83%71.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$5.98M39.3%
Operating Free Cash Flow-$5.98M39.3%

Valuation

MetricQ2 2025YoY Change
Price to Earnings0.09-
Price to Book-0.06-13.22-0.271.25-20.05%
Price to Sales25.02143.4473.102.97-94.07%
Price to Tangible Book Value-0.06-13.22-0.271.25-20.05%
Enterprise Value to EBITDA-0.03-0.37-0.133.58-119.84%
Return on Equity-1096.5%-2255.4%-576.1%1224.3%-1074.08%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.